Drug intelligence / Profile preview

NT-0111

Development stage: Unknown
Lead developer: Nova Paths
Modality: Small Molecules

Overview

NT-0111 is a small-molecule inhibitor targeting Carbonic Anhydrase IX (CAIX), an enzyme that is highly overexpressed in hypoxic tumor environments and plays a critical role in regulating intracellular and extracellular pH. By inhibiting CAIX, NT-0111 disrupts the survival mechanisms of cancer cells in acidic microenvironments, potentially limiting tumor growth, survival, and metastasis. Developed by Nova Paths (also known as Nova Therapeutics) in collaboration with the BC Cancer Foundation, the agent is being investigated for the treatment of various solid and hematological malignancies. Clinical development has included a Phase Ib study in pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine, with further Phase II trials planned for 2025-2026.

Targets

CA9 (Carbonic anhydrase IX)

Beyond the preview

Go deeper on NT-0111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NT-0111.

Explore the full profile